MEMaximilian von Eynatten

Maximilian von Eynatten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maximilian von Eynatten has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Hamann

    Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany

    2 shared publications
  • Peter P. Nawroth

    Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany

    2 shared publications
  • Angelika Bierhaus

    Department of Medicine I (Endocrinolgy and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany

    1 shared publication
  • Dietrich Rothenbacher

    Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany

    1 shared publication
  • Dorothee Twardella

    Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany

    1 shared publication
  • Gottfried Rudofsky

    Department of Medicine I (Endocrinolgy and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany

    1 shared publication

Latest Publications

  • Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease

    by Maximilian von Eynatten, Andreas Hamann, Dorothee Twardella, Peter P. Nawroth, Hermann Brenner, Dietrich Rothenbacher

    Background: Adiponectin, an adipocyte-derived hormone, appears to be a modulator of lipid metabolism and systemic inflammation and is present in particularly low concentrations in patients with coronary heart disease (CHD). However, the clinical importance of adiponectin in individuals at markedly high risk for future cardiovascular morbidity and mortality has not been fully elucidated. We examined the associations between serum adiponectin and several biomarkers related to cardiovascular disease and heart failure in a large high-risk population comprising patients with prevalent CHD.


  • The Role of Adiponectin in Atherosclerosis: do Lipids Tip the scales?

    by Maximilian von Eynatten, Jochen G Schneider

    Adiponectin may play a role in the pathophysiology of atherosclerosis, dyslipidemia and coronary artery disease. Thus, adiponectin administration diminishes atherosclerotic burden in experimental mouse models and high plasma adiponectin concentrations are associated with lower risk of myocardial infarction in men. Dyslipidemia is the strongest risk factor for coronary artery disease. Decreased adiponectin is associated with an atherogenic lipid profile of low high-density lipoprotein cholesterol and elevated triglycerides. However, little attention has been paid to this phenomenon to date. It is known that adiponectin is an important regulator of hepatic and muscle fatty acid oxidation. Two recent human studies suggest that adiponectin may influence activity and/or expression of hepatic lipase and lipoprotein lipase. These two plasma enzymes directly regulate concentrations of circulating lipoproteins. Future research may reveal the role of adiponectins in lipid metabolism, especially in affecting plasma high-density lipoprotein cholesterol levels. Adiponectin administration and regulation of the pathways controlling its production may prove beneficial as a therapeutic strategy in atherogenic dyslipidemia and atherosclerosis.


  • Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia

    by Maximilian von Eynatten, Jochen G. Schneider, Per M. Humpert, Gottfried Rudofsky, Nikolaus Schmidt, Patrizia Barosch, Andreas Hamann, Michael Morcos, Joerg Kreuzer, Angelika Bierhaus, et al.

    OBJECTIVE—Adiponectin is a plasma protein expressed in adipose tissue. Hypoadiponectinemia is associated with low HDL cholesterol and high plasma triglycerides, which also characterize lipoprotein lipase (LPL) deficiency syndromes. Recently, dramatically increased LPL activity was reported in mice overexpressing adiponectin. We therefore speculated that adiponectin may directly affect LPL in humans. RESEARCH DESIGN AND METHODS—We measured plasma adiponectin and postheparin LPL in 206 nondiabetic men and in a second group of 110 patients with type 2 diabetes. Parameters were correlated with markers of systemic inflammation (C-reactive protein [CRP]) and insulin resistance (homeostatis model assessment of insulin resistance [HOMA-IR]). RESULTS—Nondiabetic subjects with decreased plasma adiponectin had lower LPL activity (r = 0.42, P < 0.0001). This association of plasma adiponectin with LPL activity was confirmed in the second group of patients with type 2 diabetes (r = 0.37, P < 0.0001). Multivariate analysis revealed that adiponectin was the strongest factor influencing LPL activity, accounting for 23% of the variation in LPL activity in nondiabetic subjects and for 26% of the variation in LPL activity in type 2 diabetic patients. These associations were independent of plasma CRP and HOMA-IR. CONCLUSIONS—These results demonstrate an association of decreased postheparin LPL activity with low plasma adiponectin that is independent of systemic inflammation and insulin resistance. Therefore, LPL may represent a link between low adiponectin levels and dyslipidemia in both nondiabetic individuals and patients with type 2 diabetes.